Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.56 |
| ▸ | MEN1 | O00255 | 3/20 | 0.56 |
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.53 |
| ▸ | LTA4H | P09960 | 1/20 | 0.51 |
| ▸ | CXCR6 | O00574 | 1/20 | 0.51 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | XBP1 | P17861 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3874160 | 1.00 | KMT2A (0.56) | KMT2AMEN1MAPTMAPK1LTA4H | |
| SCHEMBL3873003 | 0.90 | OPRK1 (0.58) | KMT2AMEN1MAPTLTA4HOPRK1 | |
| SCHEMBL3873002 | 0.90 | OPRK1 (0.58) | KMT2AMEN1MAPTLTA4HOPRK1 | |
| SCHEMBL22582544 | 0.84 | KMT2A (0.67) | KMT2AMEN1MAPTMAPK1OPRK1 | |
| SCHEMBL22582539 | 0.84 | KMT2A (0.67) | KMT2AMEN1MAPTMAPK1OPRK1 | |
| SCHEMBL22582542 | 0.84 | KMT2A (0.67) | KMT2AMEN1MAPTMAPK1OPRK1 | |
| SCHEMBL3869200 | 0.82 | MEN1 (0.59) | KMT2AMEN1MAPTMAPK1LTA4H | |
| SCHEMBL3869202 | 0.82 | MEN1 (0.59) | KMT2AMEN1MAPTMAPK1LTA4H | |
| SCHEMBL3871504 | 0.81 | MEN1 (0.57) | KMT2AMEN1MAPTMAPK1LTA4H | |
| SCHEMBL13853081 | 0.81 | MEN1 (0.57) | KMT2AMEN1MAPTMAPK1LTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1891064-B1 | N-AMIDE DERIVATIVES OF 8-AZABICYCLO[3.2.1]OCT-3-YL AS CCR1 ANTAGONISTS | ALMIRALL SA (ES) | 2009-09-02 | — | — | EP | disclosed |
| US-20090130090-A1 | N-amide Derivatives of 8-Azabicyclo[3.2.1]OCT-3-YL AS CCR1 Antagonists | LABORATORIOS ALMIRALL, S.A. (ES) | 2009-05-21 | — | — | US | disclosed |
| EP-1891064-A1 | N-AMIDE DERIVATIVES OF 8-AZABICYCLO[3.2.1]OCT-3-YL AS CCR1 ANTAGONISTS | Laboratorios Almirall, S.A. (ES) | 2008-02-27 | — | — | EP | disclosed |
| WO-2006133802-A1 | N-AMIDE DERIVATIVES OF 8-AZABICYCLO[3.2.1]OCT-3-YL AS CCR1 ANTAGONISTS | LABORATORIOS ALMIRALL, S.A. (ES) | 2006-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090130090-A1 | N-amide Derivatives of 8-Azabicyclo[3.2.1]OCT-3-YL AS CCR1 Antagonists | CCR1, CCR3, CCR8 | KMT2A 2987/4885MEN1 4445/4885MAPT 4128/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.